



2026 Synthetic Cannabinoid/Designer Drugs (SCDD) Drug Listing

Challenges will include a mix of drugs from the list below.
Program challenges may change due to drug sourcing constraints.

2-chloromethcathinone

2-methylmethcathinone (NEW)

3-chloromethcathinone (NEW)

3-methylmethcathinone

3,4-methylenedioxy- α -pyrrolidinohexanophenone (3,4-MDPHP)

3,4-methylenedioxypyrovalerone (MDPV)

4-chloro- α -PVP

4-fluoro ABUTINACA N-(4-hydroxybutyl) metabolite

4-fluoro MDMB-BICA butanoic acid metabolite (4-fluoro MDMB-BUTICA butanoic acid metabolite)

4-fluoro-MDMB-BUTICA N-(4-hydroxybutyl) metabolite (NEW)

4-fluoro MDMB-BUTINACA butanoic acid metabolite

4-methylmethcathinone (Mephedrone)

5-fluoro ADB 3,3-dimethylbutanoic acid (5-fluoro MDMB-PINACA 3,3-dimethylbutanoic acid)

5-fluoro AMB 3-methylbutanoic acid (5-fluoro MMB-PINACA 3-methylbutanoic acid)

5-fluoro MDMB-PICA 3,3-dimethylbutanoic acid (5-fluoro MDMB-PICA metabolite 7)

5-fluoro MDMB-PICA metabolite 8 (MDMB-2201 butanoic acid metabolite 8, 5-fluoro MDMB-PICA metabolite M06, 5-fluoro MDMB-PICA N-propionic acid metabolite) (NEW)

5-fluoro MDMB-PINACA metabolite 7 (5-fluoro ADB-metabolite 7)

5-fluoro PB-22 3-carboxyindole

AB-CHMINACA 3-methylbutanoic acid (AB-CHMINACA metabolite 2)

AB-CHMINACA metabolite M1A

AB-CHMINACA metabolite M1B

ADB-4en-PINACA

ADB-5'Br-BUTINACA 3,3-dimethylbutanoic acid metabolite

ADB-5'Br-PINACA

ADB-BINACA

ADB-BUTINACA N-(4-hydroxybutyl) metabolite



2026 Synthetic Cannabinoid/Designer Drugs (SCDD) Drug Listing

Challenges will include a mix of drugs from the list below.
Program challenges may change due to drug sourcing constraints.

ADB-BUTINACA N-butanoic acid metabolite (NEW)

ADB-CHMINACA 3,3-dimethylbutanoic acid (ADB-CHMINACA metabolite 2)

ADB-FUBIATA 3,3-dimethylbutanoic acid metabolite

Alpha-PHP

Alpha-PiHP

Alpha-PVP

AM-2201 N-(4-hydroxypentyl) metabolite

BB-22 3-carboxyindole

Benzylone (3,4-methylenedioxy-N-benzylcathinone)

Butylone

BZO-4en-POXIZID

CH-PIATA

CH-PIATA N-pentanoic acid metabolite

CUMYL-4CN-BINACA N-butanoic acid metabolite (4-cyano CUMYL-BUTINACA metabolite 10)

Ethylone

Eutylone

Fluorexetamine (NEW)

FUB-AMB 3-methylbutanoic acid (MMB-FUBINACA 3-methylbutanoic acid)

FUB-PB-22 3-carboxyindole

JWH-018 N-pentanoic acid

JWH-073 N-butanoic acid metabolite

MAB-CHMINACA metabolite M3 (NEW)

MDMB-4en-PINACA butanoic acid metabolite

MDMB-BUTINACA butanoic acid metabolite

MDMB-FUBICA 3,3-dimethylbutanoic acid (MDMB-FUBICA metabolite 3)

MDMB-FUBINACA 3,3-dimethylbutanoic acid (MDMB-FUBINACA metabolite 1)



COLLEGE of AMERICAN PATHOLOGISTS

Laboratory Quality Solutions

2026 Synthetic Cannabinoid/Designer Drugs (SCDD) Drug Listing

Challenges will include a mix of drugs from the list below.
Program challenges may change due to drug sourcing constraints.

MDMB-INACA 3,3-dimethylbutanoic acid metabolite (NEW)

MDMB-PICA 3,3-dimethylbutanoic acid metabolite (NEW)

N-butyl pentylone

N-cyclohexyl butylone

N-cyclohexyl methylone

N,N-dimethylpentylone

N-propyl butylone

Pentylone

PV8 (α -PHPP) NEW

UR-144 N-pentanoic acid

XLR-11 N-(4-hydroxypentyl) metabolite